Chengdu New Radiomedicine

Executive Summary

Chengdu New Radiomedicine is a private Chinese biotech specializing in targeted radiopharmaceuticals for oncology and diagnostic imaging. Founded in 2018, the company leverages proprietary platforms to conjugate radioactive isotopes with tumor-targeting molecules, enabling precise radiation delivery to cancer cells while sparing healthy tissue. Its lead pipeline includes several novel radiopharmaceuticals in Phase 2 clinical trials for solid tumors, with a focus on prostate cancer and neuroendocrine tumors. The company aims to address key limitations in current radiotherapy by improving therapeutic index and enabling real-time diagnostic imaging through theranostic pairs. With a strong intellectual property portfolio and a seasoned management team, Chengdu New Radiomedicine is well-positioned to capture a share of the growing global radiopharmaceutical market, which is projected to exceed $10 billion by 2030. Despite being in a competitive landscape, the company differentiates itself through novel isotope selection (e.g., Actinium-225, Lutetium-177) and proprietary chelation chemistry that enhances stability and tumor uptake. Chengdu New Radiomedicine has established partnerships with leading academic medical centers in China and is pursuing both domestic (NMPA) and international (FDA) regulatory pathways. Near-term value inflection points include data readouts from ongoing Phase 2 trials and potential regulatory submissions. While the company remains privately funded, its innovative approach and early clinical promise warrant attention from investors seeking exposure to the rapidly expanding radiopharmaceutical sector.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for Lead Radiopharmaceutical Candidate (Prostate Cancer)60% success
• Q2 2027IND Filing for Next-Generation Theranostic Pair70% success
• Q3 2026Strategic Partnership or Licensing Deal for China Commercialization50% success